ScholarIQanswers from OpenAlex
Gastric Cancer Management and Outcomes
TopicLeading institutions, researchers & key papers
Gastric Cancer Management and Outcomes is a topic indexed in ScholarIQ from OpenAlex.
What is known about Gastric Cancer Management and Outcomes?
ScholarIQrecord summary
This cluster of papers represents a comprehensive exploration of gastric cancer, covering topics such as chemotherapy, endoscopic resection, molecular characterization, lymph node dissection, adjuvant and neoadjuvant therapy, clinical practice guidelines, metastatic gastric cancer, and survival analysis.
How many works does Gastric Cancer Management and Outcomes have?
ScholarIQindexed works
Gastric Cancer Management and Outcomes has 690 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Gastric Cancer Management and Outcomes?
ScholarIQopenalex
The OpenAlex for Gastric Cancer Management and Outcomes is on the source record.
What are the most-cited papers on Gastric Cancer Management and Outcomes?
ScholarIQmost cited works
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi, Taira Kinoshitá, Masashi Fujii, Atsushi Nashimoto, Hiroshi Furukawa, Toshifusa Nakajima, Yasuo Ohashi, Hiroshi Imamura, Masayuki Higashino, Yoshitaka Yamamura, Akira Kurita, Kuniyoshi Arai
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
Ilfet Songun, Hein Putter, Elma Meershoek‐Klein Kranenbarg, Mitsuru Sasako, Cornelis JH van de Velde
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Mitsuru Sasako, Shinichi Sakuramoto, Hitoshi Katai, Taira Kinoshitá, Hiroshi Furukawa, Toshiharu Yamaguchi, Atsushi Nashimoto, Masashi Fujii, Toshifusa Nakajima, Yasuo Ohashi
Where is Gastric Cancer Management and Outcomes research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Gastric Cancer Management and Outcomes is open access?
ScholarIQopen access share
67%OPEN ACCESS